Biotech Values

[biomaven0]

Was "Not Non-inferior" also "statistically inferior"?

Conceivably - it was a very large (900 person) trial, so I guess it depends on the non-inferiority margin.

Weird result - Bydureon did much worse than in its other trials (1.3% vs range of 1.5% to 1.9% in its other five trials, and Victoza performed right at the top of its historical range.

Was it also clinically inferior?

Maybe not. Substantially less nausea/vomiting for Bydureon, and of course there is no need for a daily injection.

Can't see this affecting approval one way or the other, but obviously a serious hit for their eventual sales.

(No position in AMLN, but I do hold some Novo Nordisk).